Modeling Longitudinal Preclinical Tumor Size Data to Identify Transient Dynamics in Tumor Response to Antiangiogenic Drugs

@inproceedings{Hutchinson2016ModelingLP,
  title={Modeling Longitudinal Preclinical Tumor Size Data to Identify Transient Dynamics in Tumor Response to Antiangiogenic Drugs},
  author={L G Hutchinson and H‐J Mueller and EA Gaffney and Philip K. Maini and Jonathan Wagg and Alex Phipps and Christophe Boetsch and H Byrne and Benjamin Ribba},
  booktitle={CPT: pharmacometrics & systems pharmacology},
  year={2016}
}
Experimental evidence suggests that antiangiogenic therapy gives rise to a transient window of vessel normalization, within which the efficacy of radiotherapy and chemotherapy may be enhanced. Preclinical experiments that measure components of vessel normalization are invasive and expensive. We have developed a mathematical model of vascular tumor growth from preclinical time-course data in a breast cancer xenograft model. We used a mixed-effects approach for model parameterization, leveraging… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 44 references

A review of mixed-effects models of tumor growth and effects of anticancer drug treatment used in population analysis

  • B Ribba
  • CPT Pharmacometrics Syst. Pharmacol
  • 2014

Initiation, extension, and maturation of new blood vessels modulated by vascular endothelial growth factor, angiopoietins, platelet-derived growth factor-B, and pericytes

  • X. Zheng, G. Young Koh, Jackson, T. A continuous model of angiogenesis
  • Discr. Contin. Dyn. Syst. B 18, 1109–1154
  • 2013

Similar Papers

Loading similar papers…